Romano Silvestri

List of Publications by Year
in descending order

147 papers	5,664 citations	76326 40 h-index	91884 69 g-index
158 all docs	158 docs citations	158 times ranked	6671 citing authors

#	Article	IF	Citations
1	Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates, 2022, 60, 100788.	14.4	15
2	Anticancer Activity of (S)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(1-oxo-1-((pyridin-4-ylmethyl)amino)propan-2-yl)-1H-indole-2-carboxamide (RS4690), a New Dishevelled 1 Inhibitor. Cancers, 2022, 14, 1358.	4.7	4
3	Exploring <scp>CCRL2</scp> Chemerin binding using Accelerated Molecular Dynamics. Proteins: Structure, Function and Bioinformatics, 2022, , .	2.6	3
4	RS-5645 attenuates inflammatory cytokine storm induced by SARS-CoV-2 spike protein and LPS by modulating pulmonary microbiota. International Journal of Biological Sciences, 2021, 17, 3305-3319.	6.4	9
5	CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme. European Journal of Pharmacology, 2021, 897, 173936.	3.5	11
6	RS4651 suppresses lung fibroblast activation via the TGF-Î²1/SMAD signalling pathway. European Journal of Pharmacology, 2021, 903, 174135.	3.5	4
7	Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia. European Journal of Medicinal Chemistry, 2021, 221, 113532.	5.5	12
8	Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of Resistance. Pharmaceuticals, 2021, 14, 1006.	3.8	0
9	Targeting PDZ domains as potential treatment for viral infections, neurodegeneration and cancer. Biology Direct, 2021, 16, 15.	4.6	12
10	Emerging Therapeutic Agents for Colorectal Cancer. Molecules, 2021, 26, 7463.	3.8	14
11	Discovery of New 1,1â€²-Biphenyl-4-sulfonamides as Selective Subnanomolar Human Carbonic Anhydrase II Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 633-637.	2.8	2
12	Structure-activity relationship studies and inÂvitro and inÂvivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies. European Journal of Medicinal Chemistry, 2020, 185, 111828.	5.5	5
13	HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53. Neuro-Oncology, 2020, 22, 550-562.	1.2	10
14	Design, Synthesis and Discovery of N,Nâ€™â€Carbazoylâ€arylâ€urea Inhibitors of Zika NS5 Methyltransferase and Virus Replication. ChemMedChem, 2020, 15, 385-390.	3.2	16
15	Mutational analysis of the essential lipopolysaccharide-transport protein LptH of Pseudomonas aeruginosa to uncover critical oligomerization sites. Scientific Reports, 2020, 10, 11276.	3.3	6
16	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains. European Journal of Medicinal Chemistry, 2020, 208, 112696.	5.5	10
17	Modeling Epac1 interactions with the allosteric inhibitor AM-001 by co-solvent molecular dynamics. Journal of Computer-Aided Molecular Design, 2020, 34, 1171-1179.	2.9	2
18	Sulfonamide Inhibitors of Î²â€Catenin Signaling as Anticancer Agents with Different Output on câ€MYC. ChemMedChem, 2020, 15, 2264-2268.	3.2	5

#	Article	IF	Citations
19	Targeting the Interaction between the SH3 Domain of Grb2 and Gab2. Cells, 2020, 9, 2435.	4.1	7
20	Discovery of Zika Virus NS2B/NS3 Inhibitors That Prevent Mice from Life-Threatening Infection and Brain Damage. ACS Medicinal Chemistry Letters, 2020, 11, 1869-1874.	2.8	14
21	Towards modern anticancer agents that interact with tubulin. European Journal of Pharmaceutical Sciences, 2019, 131, 58-68.	4.0	34
22	Switching on the activity of 1,5-diaryl-pyrrole derivatives against drug-resistant ESKAPE bacteria: Structure-activity relationships and mode of action studies. European Journal of Medicinal Chemistry, 2019, 178, 500-514.	5.5	21
23	Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B. Molecules, 2019, 24, 1739.	3.8	25
24	Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. Cardiovascular Research, 2019, 115, 1766-1777.	3.8	25
25	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. Biochemical Pharmacology, 2019, 163, 111-118.	4.4	16
26	Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents. ACS Medicinal Chemistry Letters, 2019, 10, 499-503.	2.8	13
27	Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661775344.	0.6	14
28	New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 283-297.	5.5	30
29	Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects. British Journal of Clinical Pharmacology, 2018, 84, 1566-1574.	2.4	73
30	A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist. Biochemistry, 2018, 57, 839-851.	2.5	21
31	Î²-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. Oncogene, 2018, 37, 3301-3316.	5.9	18
32	Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells. ACS Chemical Neuroscience, 2018, 9, 85-99.	3.5	22
33	Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. Journal of Medicinal Chemistry, 2018, 61, 8402-8416.	6.4	26
34	Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 444-451.	5.2	27
35	p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. OncoImmunology, 2017, 6, e1264564.	4.6	29
36	3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin. ACS Medicinal Chemistry Letters, 2017, 8, 521-526.	2.8	8

#	Article	IF	Citations
37	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents. Journal of Medicinal Chemistry, 2017, 60, 6528-6547.	6.4	19
38	Annurca apple (M. pumila Miller cv Annurca) extracts act against stress and ageing in S. cerevisiae yeast cells. BMC Complementary and Alternative Medicine, 2017, 17, 200.	3.7	17
39	Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study. European Journal of Medicinal Chemistry, 2017, 140, 528-541.	5.5	11
40	Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structureâ€“Activity Relationship Studies and Pharmacological Activity. Journal of Medicinal Chemistry, 2017, 60, 8115-8130.	6.4	19
41	Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1091-1101.	5.2	28
42	N-Pyrrylarylsulfones with High Therapeutic Potential. Molecules, 2017, 22, 434.	3.8	7
43	Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules. Oncotarget, 2017, 8, 19738-19759.	1.8	19
44	Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Molecules, 2016, 21, 221.	3.8	24
45	New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2016, 59, 9760-9773.	6.4	35
46	VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection. European Journal of Medicinal Chemistry, 2016, 115, 453-462.	5.5	6
47	Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments. Scientific Reports, 2015, 5, 15453.	3.3	41
48	In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virology Journal, 2015, 12, 106.	3.4	28
49	Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells. Cancer Biology and Therapy, 2015, 16, 1820-1829.	3.4	6
50	Structure-Based Lead Optimization and Biological Evaluation of BAX Direct Activators as Novel Potential Anticancer Agents. Journal of Medicinal Chemistry, 2015, 58, 2135-2148.	6.4	41
51	Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. Journal of Medicinal Chemistry, 2015, 58, 5979-5988.	6.4	28
52	New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. Journal of Medicinal Chemistry, 2015, 58, 5789-5807.	6.4	51
53	New Frontiers in Selective Human MAO-B Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 6717-6732.	6.4	184
54	Pharmacological folding chaperones act as allosteric ligands of Frizzled4. Nature Chemical Biology, 2015, 11, 280-286.	8.0	35

#	Article	IF	Citations
55	Discovery of 1,1â€²-Biphenyl-4-sulfonamides as a New Class of Potent and Selective Carbonic Anhydrase XIV Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 8564-8572.	6.4	40
56	New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2. European Journal of Medicinal Chemistry, 2015, 90, 497-506.	5.5	25
57	A New, Simple, and High-Yielding Synthesis of 2,9-Dihydro-1H-pyrido[3,4-b]indol-1-ones. Synthesis, 2014, 46, 2093-2097.	2.3	8
58	Indolylarylsulfones Carrying a Heterocyclic Tail as Very Potent and Broad Spectrum HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 9945-9957.	6.4	42
59	New Pyrrole Derivatives with Potent Tubulin Polymerization Inhibiting Activity As Anticancer Agents Including Hedgehog-Dependent Cancer. Journal of Medicinal Chemistry, 2014, 57, 6531-6552.	6.4	80
60	Discovery of Biarylaminoquinazolines as Novel Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 4598-4605.	6.4	28
61	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2014, 80, 101-111.	5.5	21
62	An High-Throughput In Vivo Screening System to Select H3K4-Specific Histone Demethylase Inhibitors. PLoS ONE, 2014, 9, e86002.	2.5	14
63	Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as New Glycogen Synthase Kinase-3Î² Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 10066-10078.	6.4	39
64	Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 123-149.	6.4	107
65	New Prospects for Vinblastine Analogues as Anticancer Agents. Journal of Medicinal Chemistry, 2013, 56, 625-627.	6.4	51
66	Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. Antiviral Research, 2013, 98, 12-18.	4.1	87
67	Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors. European Journal of Medicinal Chemistry, 2013, 66, 221-227.	5.5	24
68	Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors. Future Medicinal Chemistry, 2013, 5, 2141-2156.	2.3	17
69	De novo computer-aided design of novel antiviral agents. Drug Discovery Today: Technologies, 2012, 9, e213-e218.	4.0	2
70	Venting-while-Heating Microwave-Assisted Synthesis of 3-Arylthioindoles. ACS Combinatorial Science, 2012, 14, 258-262.	3.8	47
71	Apple Can Act as Anti-Aging on Yeast Cells. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-8.	4.0	23
72	Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor. Journal of Medicinal Chemistry, 2012, 55, 5627-5631.	6.4	54

#	Article	IF	Citations
73	New Nitrogen Containing Substituents at the Indole-2-carboxamide Yield High Potent and Broad Spectrum Indolylarylsulfone HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 6634-6638.	6.4	52
74	The Tubulin Colchicine Domain: a Molecular Modeling Perspective. ChemMedChem, 2012, 7, 33-42.	3.2	138
75	Open Vessel and Cooling while Heating Microwave-Assisted Synthesis of Pyridinyl N-Aryl Hydrazones. ACS Combinatorial Science, 2011, 13, 2-6.	3.8	24
76	Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: New Cyclic Substituents at Indole-2-carboxamide. Journal of Medicinal Chemistry, 2011, 54, 1587-1598.	6.4	137
77	Design and Synthesis of 2-Heterocyclyl-3-arylthio-1H-indoles as Potent Tubulin Polymerization and Cell Growth Inhibitors with Improved Metabolic Stability. Journal of Medicinal Chemistry, 2011, 54, 8394-8406.	6.4	70
78	Mechanism of Interaction of Novel Indolylarylsulfone Derivatives with K103N and Y181I Mutant HIV-1 Reverse Transcriptase in Complex with its Substrates. Antiviral Chemistry and Chemotherapy, 2011, 22, 107-118.	0.6	7
79	1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: An effective scaffold for the design of either CB1 or CB2 receptor ligands. European Journal of Medicinal Chemistry, 2011, 46, 5641-5653.	5.5	15
80	Drug-induced inhibition of tubulin polymerization induces mitochondrion-mediated apoptosis in yeast. Cell Cycle, 2011, 10, 3208-3209.	2.6	7
81	Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands. European Journal of Medicinal Chemistry, 2010, 45, 5878-5886.	5.5	7
82	Pyrrolo[1,2â€b][1,2,5]benzothiadiazepines (PBTDs) exert their antiâ€proliferative activity by interfering with Aktâ€“mTOR signaling and bax:bclâ€2 ratio modulation in cells from chronic myeloid leukemic patients. Cancer Science, 2010, 101, 991-1000.	3.9	6
83	Arylthioindoles: Promising compounds against cancer cell proliferation. Oncology Letters, 2010, 1, 109-112.	1.8	10
84	Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Antiviral Chemistry and Chemotherapy, 2010, 20, 213-237.	0.6	57
85	Radiosynthesis and in vivo evaluation of [11C]-labelled pyrrole-2-carboxamide derivates as novel radioligands for PET imaging of monoamine oxidase A. Nuclear Medicine and Biology, 2010, 37, 459-467.	0.6	13
86	Enantioselective HPLC combined with spectroscopic methods: A valid strategy to determine the absolute configuration of potential Î²-secretase inhibitors. Talanta, 2010, 82, 1306-1312.	5.5	11
87	A Screen for Kinetochore-Microtubule Interaction Inhibitors Identifies Novel Antitubulin Compounds. PLoS ONE, 2010, 5, e11603.	2.5	16
88	Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzymeâ€“substrate complex. Antiviral Research, 2009, 81, 47-55.	4.1	16
89	Boom in the development of nonâ€peptidic Î²â€secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Medicinal Research Reviews, 2009, 29, 295-338.	10.5	120
90	Synthetic strategies of nonpeptidic Î²â€secretase (BACE1) inhibitors. Journal of Heterocyclic Chemistry, 2009, 46, 10-17.	2.6	8

#	Article	IF	Citations
91	Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile. Bioorganic and Medicinal Chemistry, 2009, 17, 5549-5564.	3.0	15
92	Study of the effects of a new pyrazolecarboxamide: Changes in mitochondria and induction of apoptosis. International Journal of Biochemistry and Cell Biology, 2009, 41, 1890-1898.	2.8	15
93	New Arylthioindoles and Related Bioisosteres at the Sulfur Bridging Group. 4. Synthesis, Tubulin Polymerization, Cell Growth Inhibition, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2009, 52, 7512-7527.	6.4	87
94	Indolylarylsulfones Bearing Natural and Unnatural Amino Acids. Discovery of Potent Inhibitors of HIV-1 Non-Nucleoside Wild Type and Resistant Mutant Strains Reverse Transcriptase and Coxsackie B4 Virus. Journal of Medicinal Chemistry, 2009, 52, 1922-1934.	6.4	54
95	Synthesis, structureâ€“activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorganic and Medicinal Chemistry, 2008, 16, 9729-9740.	3.0	31
96	Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. Journal of Medicinal Chemistry, 2008, 51, 1560-1576.	6.4	65
97	1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, New Imidazoles with Potent Activity againstCandida albicansand Dermatophytes. Synthesis, Structureâ^'Activity Relationship, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2008, 51, 3841-3855.	6.4	28
98	AN IMPROVED SYNTHESIS OF ETHYL 5-CHLORO-4-FLUORO-1H-INDOLE-2-CARBOXYLATE. Organic Preparations and Procedures International, 2008, 40, 204-208.	1.3	6
99	Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies. Expert Opinion on Drug Discovery, 2007, 2, 87-114.	5.0	5
100	Arylthioindole Inhibitors of Tubulin Polymerization. 3. Biological Evaluation, Structureâ^'Activity Relationships and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2007, 50, 2865-2874.	6.4	177
101	New Pyrrole Inhibitors of Monoamine Oxidase:Â Synthesis, Biological Evaluation, and Structural Determinants of MAO-A and MAO-B Selectivity. Journal of Medicinal Chemistry, 2007, 50, 922-931.	6.4	114
102	Indolyl Aryl Sulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors:â€‰ Role of Two Halogen Atoms at the Indole Ring in Developing New Analogues with Improved Antiviral Activity. Journal of Medicinal Chemistry, 2007, 50, 5034-5038.	6.4	56
103	Indole, a core nucleus for potent inhibitors of tubulin polymerization. Medicinal Research Reviews, 2007, 27, 209-238.	10.5	326
104	PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells. BMC Cancer, 2007, 7, 207.	2.6	6
105	New Arylthioindoles:Â Potent Inhibitors of Tubulin Polymerization. 2. Structureâ^'Activity Relationships and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2006, 49, 947-954.	6.4	331
106	Design, Molecular Modeling, Synthesis, and Anti-HIV-1 Activity of New Indolyl Aryl Sulfones. Novel Derivatives of the Indole-2-carboxamide. Journal of Medicinal Chemistry, 2006, 49, 3172-3184.	6.4	157
107	Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs):â€‰ A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. Journal of Medicinal Chemistry, 2006, 49, 5840-5844.	6.4	56
108	Direct HPLC enantioseparation of chiral aptazepine derivatives on coated and immobilized polysaccharide-based chiral stationary phases. Chirality, 2006, 18, 621-632.	2.6	33

#	Article	IF	Citations
109	Indolyl Aryl Sulphones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Synthesis, Biological Evaluation and Binding Mode Studies of New Derivatives at Indole-2-carboxamide. Antiviral Chemistry and Chemotherapy, 2006, 17, 59-77.	0.6	25
110	Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Expert Opinion on Therapeutic Patents, 2006, 16, 939-962.	5.0	9
111	Comparative study between the polysaccharide-based Chiralcel OJ and Chiralcel OD CSPs in chromatographic enantioseparation of imidazole analogues of Fluoxetine and Miconazole. Journal of Separation Science, 2005, 28, 627-634.	2.5	26
112	Indolyl Aryl Sulfones (IASs): Development of Highly Potent NNRTIs Active Against wt-HIV-1 and Clinically Relevant Drug Resistant Mutants. Current Pharmaceutical Design, 2005, 11, 3779-3806.	1.9	17
113	High Potency of Indolyl Aryl Sulfone Nonnucleoside Inhibitors towards Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants Is Due to Selective Targeting of Different Mechanistic Forms of the Enzyme. Antimicrobial Agents and Chemotherapy, 2005, 49, 4546-4554.	3.2	19
114	Docking and 3-D QSAR Studies on Indolyl Aryl Sulfones. Binding Mode Exploration at the HIV-1 Reverse Transcriptase Non-Nucleoside Binding Site and Design of Highly ActiveN-(2-Hydroxyethyl)carboxamide andN-(2-Hydroxyethyl)carbohydrazide Derivatives. Journal of Medicinal Chemistry, 2005, 48, 213-223.	6.4	77
115	Novel 1-[2-(Diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. A Structureâ"Activity Relationship Investigation. Journal of Medicinal Chemistry, 2005, 48, 4378-4388.	6.4	51
116	Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzotriazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4,14b-tetrahydro-2H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzothiadiazepine 10,10-dioxide (tiaaptazepine). Il Farmaco, 2005, 60, 931-937.	0.9	3
117	Anti-HIV-1 activity of pyrryl aryl sulfone (PAS) derivatives: synthesis and SAR studies of novel esters and amides at the position 2Âof the pyrrole nucleus. Il Farmaco, 2004, 59, 201-210.	0.9	40
118	Anti-HIV-1 Activity of Pyrryl Aryl Sulfone (PAS) Derivatives: Synthesis and SAR Studies of Novel Esters and Amides at the Position 2 of the Pyrrole Nucleus.. ChemInform, 2004, 35, no.	0.0	0
119	Arylthioindoles, Potent Inhibitors of Tubulin Polymerization. Journal of Medicinal Chemistry, 2004, 47, 6120-6123.	6.4	260
120	Simple, Short Peptide Derivatives of a Sulfonylindolecarboxamide (L-737,126) Active in Vitro against HIV-1 Wild Type and Variants Carrying Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations. Journal of Medicinal Chemistry, 2004, 47, 3892-3896.	6.4	53
121	Imidazole Analogues of Fluoxetine, a Novel Class of Anti-CandidaAgents. Journal of Medicinal Chemistry, 2004, 47, 3924-3926.	6.4	43
122	Simple, Potent, and Selective Pyrrole Inhibitors of Monoamine Oxidase Types A and B. Journal of Medicinal Chemistry, 2003, 46, 917-920.	6.4	47
123	Novel Indolyl Aryl Sulfones Active against HIV-1 Carrying NNRTI Resistance Mutations:Â Synthesis and SAR Studies. Journal of Medicinal Chemistry, 2003, 46, 2482-2493.	6.4	149
124	Synthesis, Biological Evaluation, and Binding Mode of Novel 1-[2-(Diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles Targeted at the HIV-1 Reverse Transcriptase. Journal of Medicinal Chemistry, 2002, 45, 1567-1576.	6.4	65
125	A SIMPLIFIED SYNTHESIS OF ETHYL 5-CHLORO-4-FLUORO-1H-INDOLE-2-CARBOXYLATE AND ETHYL 5-CHLORO-6-FLUORO-1H-H-INDOLE-2-CARBOXYLATE. Organic Preparations and Procedures International, 2002, 34, 517-520.	1.3	8
126	1-Amino-6-chloro-2-(1H-pyrrol-2-yl)benzimidazole (RS 1350). Acta Crystallographica Section E: Structure Reports Online, 2001, 57, o819-o821.	0.2	0

#	Article	IF	Citations
127	1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 253-256.	2.2	39
128	Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorganic and Medicinal Chemistry, 2000, 8, 2305-2309.	3.0	16
129	Reductive Smiles Rearrangement of 1-[(5-Chloro-2-nitrophenyl)- sulfonyl]-1H-pyrrole-2-carbo-hydrazide to 1-Amino-6-chloro-2- (1H-pyrrol-2-yl)benzimidazole. Heterocycles, 2000, 53, 2163.	0.7	16
130	Structure-Based Design, Synthesis, and Biological Evaluation of Novel Pyrrolyl Aryl Sulfones:Â HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors Active at Nanomolar Concentrations. Journal of Medicinal Chemistry, 2000, 43, 1886-1891.	6.4	130
131	2-Sulfonyl-4-chloroanilino Moiety:Â A Potent Pharmacophore for the Anti-Human Immunodeficiency Virus Type 1 Activity of Pyrrolyl Aryl Sulfones. Journal of Medicinal Chemistry, 1996, 39, 522-530.	6.4	127
132	5H-pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A novel class of non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 1996, 4, 837-850.	3.0	44
133	Synthesis of Pyrryl Aryl Sulfones Targeted at the HIV-1 Reverse Transcriptase. Archiv Der Pharmazie, 1995, 328, 223-229.	4.1	29
134	Synthesis of 9Hâ€pyrrolo[2,1â€b][1,3,6]benzothiadiazocinâ€10(11H)â€one 4,4â€dioxide, a potential antiâ€HIVâ€1 agent. Journal of Heterocyclic Chemistry, 1995, 32, 683-685.	2.6	10
135	Heterocycles With a Benzothiadiazepine Moiety. IV. Synthesis of Novel Tetracyclic Rings by Intramolecular Cyclization of 10-Bromoacetyl-10,11-dihydro-11-ethoxycarbonyl-pyrrolo[1,2-b] [1,2,5] Benzothiadiazepine 5,5-Dioxide and Its Derivatives. Synthetic Communications, 1994, 24, 2685-2695.	2.1	16
136	Heterocycles with a benzothiadiazepine moiety.3.Synthesis of imidazo[5,1-d]pyrrolo[1,2-b][1,2,5]benzothiadiazepine 9,9-dioxide. Journal of Heterocyclic Chemistry, 1994, 31, 1033-1036.	2.6	21
137	Research on nitrogen containing heterocyclic compounds.XIX: Synthesis of 8H-imidazo[2,1-c]-s-triazolo[4,3-a]-[1,4]benzodiazepine and its 1-derivatives. Journal of Heterocyclic Chemistry, 1993, 30, 529-532.	2.6	12
138	Heterocycles with a Benzothiadiazeypine Moiety. I. Synthesis of Pyrrolo[1,2-b]-s-triazolo[3,4-d] [1,2,5]benzothiadiazepine 5,5-Dioxide. Synthetic Communications, 1992, 22, 1433-1439.	2.1	18
139	Bovine serum amine oxidase: half-site reactivity with phenylhydrazine, semicarbazide, and aromatic hydrazides. Biochemistry, 1992, 31, 2615-2621.	2.5	61
140	Research on nitrogen containing heterocyclic compounds. XVIII. Synthesis of 9Hâ€pyrrolo[2,1â€c]â€sâ€triazolo[4,3â€a][1,4]benzodiazepine, a novel tetracyclic ring of pharmaceutical interest. Journal of Heterocyclic Chemistry, 1992, 29, 1005-1007.	2.6	14
141	Researches on Antibacterial and Antifungal Agents, XIV: Thiophene Analogues of Bifonazole. Archiv Der Pharmazie, 1992, 325, 199-204.	4.1	12
142	Antibacterial and Antifungal Agents, XV: Synthesis and Antifungal Activity of Structural Analogues of Bifonazole and Ketoconazole. Archiv Der Pharmazie, 1992, 325, 687-694.	4.1	3
143	Moieties and Related Azoles. Archiv Der Pharmazie, 1990, 323, 273-280.	4.1	6
144	Potential antitumor agents. III. Synthesis of pyrazolo[3,4â€e]pyrrolo[3,4â€g]indolizine and 1Hâ€pyrazolo[3,4â€e]indolizine derivatives. Journal of Heterocyclic Chemistry, 1989, 26, 503-507.	2.6	10

#	Article	IF	Citations
145	Research on nitrogen containing heterocyclic compounds. XVI. Synthesis of 1, 3, 4, 14bâ€tetrahydroâ€2, 10â€dimethylâ€2H,10Hâ€pyrazino[2, 1â€d]pyrrolo[1, 2â€b][1, 2, 5]benzotriazepine (1:1) maleate (10â€methylâ€10â€azaaptazepine). Journal of Heterocyclic Chemistry, 1989, 26, 745-746.	2.1	17
146	Researches on Antibacterial and Antifungal Agents, X. Synthesis and Antifungal Activities of 1-{p-Methyl-Î±-[4-(1H-pyrrol-1-yl)phenyl]benzyl}azoles and Some Related Products. Archiv Der Pharmazie, 1989, 322, 369-373.	4.1	12
147	Heterocyclic systems.VIISynthesis of 1H-pyrazolo[3,4-e]indolizine derivatives. Journal of Heterocyclic Chemistry, 1987, 24, 1199-1202.	2.6	7